To the Editor:In recent years,impressive outcomes have been achieved in patients harboring human epidermal growth factor receptor 2(HER2)mutations,which accounts for 1%to 4%of cases in non-small cell lung cancer(NSCLC).
基金National Natural Science Foundation of China(Nos.81972167,82172869 and 82002419)Shanghai Shenkang Hospital Development Center(No.SHDC12019133)+1 种基金Clinical Research Foundation of Shanghai Pulmonary Hospital(No.FKLY20008)Shanghai Innovative Collaboration Project(No.2020CXJQ02)
文摘To the Editor:In recent years,impressive outcomes have been achieved in patients harboring human epidermal growth factor receptor 2(HER2)mutations,which accounts for 1%to 4%of cases in non-small cell lung cancer(NSCLC).
